This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-2 summaryPALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresIBRANCE long-term safetyGI and liver toxicitiesEffect of IBRANCE on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyRW evidenceValue of RWEWhat is real-world evidence?What is the value of RWE?P-REALITY and P-REALITY XP-REALITY OverviewP-REALITY OS and rwPFSP-REALITY X OverviewP-REALITY X OS and rwPFSIRISIRIS OverviewIRIS PFS and OSPOLARIS POLARIS OverviewPOLARIS Patient-Reported OutcomesMADELINEMADELINE OverviewMADELINE Patient CharacteristicsMADELINE Patient-Reported OutcomesPalomAGEPalomAGE OverviewRWE in Older Patients with mBCPatient-reported outcomesPALOMA-2: FACT-B scoresPALOMA-3: EORTC QLQ-C30 scoresPALOMA-3: Time to deterioration in pain symptomsDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provision ResourcesMaterials
IBRANCE-associated AEs may be effectively managed using a clear dose-modification schedule1

Adapted from IBRANCE Summary of Product Characteristics.1

Dose reductions or dose modifications due to any AE occurred in 38.4% of patients receiving IBRANCE in randomised clinical studies regardless of the combination1

*If further dose reduction below 75 mg/day is required, discontinue the treatment1

Dose Modification and Management of Haematological Toxicities1Cycle 1 Cycle 2

Cycle 3

  • CBC to be repeated on Day 1 of each following cycle
  • For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, CBCs for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated
  • Dose reductions for uncomplicated Grade 3 neutropenia should only be performed at the initiation of a cycle and not during a cycle

Dose Modification and Management of Non-haematological Toxicities1

All cyclesDose modification includes temporary dose interruptions, cycle delays, and/or reductions.
Grading according to CTCAE 4.0.2
Applies to all haematological adverse events except lymphopenia (unless associated with clinical events, e.g. opportunistic infections). ANC: Grade 1: ANC <LLN – 1500/mm3; Grade 2: ANC 1000 – <1500/mm3; Grade 3: ANC 500 – <1000/mm3; ​​​​​​​Grade 4: ANC <500/mm3Proactively monitor CBC.

AE = adverse event; ANC = absolute neutrophil count; CBC = complete blood count; CTCAE = Common Terminology Criteria for Adverse Events; HR+/HER2 - = hormone receptor-positive, human epidermal growth factor receptor 2-negative; LLN = lower limit of normal.



Additional Monitoring

Management of Interstitial Lung Disease (ILD)/Pneumonitis, Venous Thromboembolism and Febrile Neutropenia1




Across clinical studies (PALOMA-1, PALOMA-2 and PALOMA-3), 1.4% of IBRANCE-treated patients had ILD/Pneumonitis of any grade. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g. hypoxia, cough, dyspnoea). In patients who have new of worsening respiratory symptoms and are suspected to have developed ILD/pneumonitis, interrupt IBRANCE immediately and evaluate the patient. Permanently discontinue IBRANCE in patients with severe ILD or pneumonitis.1



Venous Thromboembolism

Any grade VTEs were reported in 3.2% of patients treated with IBRANCE across clinical studies (PALOMA-1, PALOMA-2 and PALOMA-3). Patients should be monitored for signs and symptoms of DVT and PE, and treated as medically appropriate.1



Febrile Neutropenia

Across clinical studies (PALOMA-1, PALOMA-2 and PALOMA-3), 1.4% of IBRANCE-treated patients experienced febrile neutropenia of any grade. In cases of febrile neutropenia, IBRANCE should be withheld until recovery of neutropenia to Grade <2 and then resumed at the next lower dose at the beginning of the following cycle.1


The overall safety profile of IBRANCE is based on pooled data from 872 patients who received palbociclib in combination with endocrine therapy (N=527 in combination with letrozole and N=345 in combination with fulvestrant) in randomised clinical studies in HR+ HER2-negative advanced or metastatic breast cancer.



For the most up-to-date safety profile information, please refer to the full IBRANCE® Summary of Product Characteristics.

ILD = interstitial lung disease, VTE = venous thromboembolism, DVT = deep vein thrombosis, PE = pulmonary embolism


References:IBRANCE Summary of Product Characteristics.

National Cancer lnstitute. CTCAE v.4.0. Available at: CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed November 2023.

Recommended dosing
IBRANCE Summary of Product Characteristics Product Characteristics Loading

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0685. November 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024